Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (1687)	11/17/2014 11:56:29 AM
From: DewDiligence_on_SI	Respond to of 3559

IMPROVE-IT ITT results: siliconinvestor.com

To: Biotech Jim who wrote (1687)	11/17/2014 1:26:45 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3559

Very modest benefit (relative ~6% reduction over 7 years on drug) from further ~15-17% reduction in LDL-C! Maybe not sufficient to change FDA minds! As DD suggested, PP analysis will be better view-point. It is clear that targeting ~50 mg/dL for LDL-C make sense in all counts (regardless what STUBORN cardiologist continue to "politically" prefer cheap Statins to be standard guidance), and that to accept this thinking someone will need to run outcome trails directly compering statins to alternative! And to show great benefit justifying "biologic" price for drug. It does not need to be in $multiple-10K range, it can be in $3-4K range per year. Nice Odyssey-alternative results.